eJHaem (Nov 2020)

Low morbidity and mortality with COVID‐19 in sickle cell disease: A single center experience

  • Preethi Ramachandran,
  • Abhilash Perisetti,
  • Balachandar Kathirvelu,
  • Mahesh Gajendran,
  • Snigdha Ghanta,
  • Ifeanyichkwu Onukogu,
  • Ted Lao,
  • Faiz Anwer

DOI
https://doi.org/10.1002/jha2.87
Journal volume & issue
Vol. 1, no. 2
pp. 608 – 614

Abstract

Read online

Abstract Coronavirus disease 2019 (COVID‐19) is caused by SARS‐CoV‐2 infection, which evolved into a global pandemic within a short time. Individuals with sickle cell disease (SCD) suffer from underlying cardiopulmonary comorbidities and are at risk of severe complications such as pneumonia, acute chest syndrome, thrombosis, stroke, and multiorgan failure. Whether COVID‐19 poses a high risk of morbidity and mortality in SCD patients remains unclear. Patients with SCD and COVID‐19 can present with overlapping clinical features such as respiratory symptoms with ground‐glass infiltrates, hyperinflammatory state, and increased risk of thromboembolism. This highlights the need to maintain a low threshold for testing for COVID‐19 infection among symptomatic and hospitalized SCD patients. We report a case series of nine hospitalized SCD patients diagnosed with COVID‐19 from March 18, 2020 to April 30, 2020 at a tertiary medical center in New York City. The mean age of the study population was 27.9 years, and interval since onset of symptoms and hospital presentation was 1–2 weeks. All patients in our series improved and were discharged home. This limited study shows that SCD patients, who are perceived to be high risk, maybe somehow protected from severe symptoms and complications of COVID‐19 infection.

Keywords